Chuncharunee Suporn, Wong Raymond, Rojnuckarin Ponlapat, Chang Cheng-Shyong, Chang Kian Meng, Lu Meng-Yao, Hwang Wen-Li, Koh Liang Piu, Chen Tsai-Yun, Leung Anskar Yh, Norasetthada Lalita, Wang Shih-Chung, Chang Ming-Chih, Wu Kang-Hsi, Issaragrisil Surapol
Ramathibodi Hospital, Bangkok, Thailand.
Department of Medicine and Therapeutics, Prince of Wales Hospital and Sir Y. K. Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, China.
Int J Hematol. 2016 Oct;104(4):454-61. doi: 10.1007/s12185-016-2053-8. Epub 2016 Jul 4.
Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5-3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.
由于全球许多市场无法获得马抗胸腺细胞球蛋白（ATG），重型再生障碍性贫血（SAA）患者只能使用兔ATG。我们旨在分析接受兔ATG作为SAA一线治疗的亚洲患者的血液学反应和总生存期（OS）。我们回顾性分析了2006年至2012年期间在四个亚洲国家的中心接受兔ATG作为SAA一线治疗的97例连续患者的病历。主要终点是接受推荐剂量范围（2.5 - 3.75mg/kg/天）兔ATG的患者的6个月和12个月总缓解率（ORR）。次要终点包括接受任何剂量兔ATG的患者的ORR和2年OS。对于接受推荐剂量范围兔ATG的患者，6个月和12个月的ORR分别为17.4%和63.6%。对于接受任何剂量兔ATG的患者，6个月和12个月的ORR分别为24.3%和68.6%。2年OS率为86.3%。兔ATG对亚洲SAA患者的治疗有效。兔ATG的12个月ORR和2年OS与马ATG的历史结果相当。
